Protalix BioTherapeutics (FRA:PBDA) Growth Rank: 1 (As of Aug. 19, 2026) — 80% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PBDA Protalix BioTherapeutics Inc FRA:PBDA
56 GF Score
Price €2.00
GF Value €1.89
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Protalix BioTherapeutics Growth Rank?

Protalix BioTherapeutics FRA:PBDA +2.15% 56 Growth Rank is 1 as of Aug. 19, 2026, which is 80% below its 10-year median of 5.00. GuruFocus rates FRA:PBDA with a GF Score™ of 56/100 and a GF Value™ of €1.89 (Fairly Valued). The stock has 4 warning signs investors should review.

Protalix BioTherapeutics has the Growth Rank of 1.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Protalix BioTherapeutics Growth Rank Related Terms

FRA:PBDA vs GLSI, DTIL, NERV: Growth Rank Comparison

For the Biotechnology subindustry, Protalix BioTherapeutics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Protalix BioTherapeutics Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Growth Rank distribution charts can be found below:

* The bar in red indicates where Protalix BioTherapeutics's Growth Rank falls into.


FRA:PBDA
56GF Score
Protalix BioTherapeutics Inc FRA:PBDA
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 1 mean?
Protalix BioTherapeutics (FRA:PBDA) has a Growth Rank of 1 as of Aug. 19, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Protalix BioTherapeutics and its competitors. This is 80% below median its historical median of 5.00. Over the past decade, Protalix BioTherapeutics' Growth Rank has ranged from 1.00 to 10.00.
Is Protalix BioTherapeutics' Growth Rank too high?
Protalix BioTherapeutics' current Growth Rank of 1 is 80% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Protalix BioTherapeutics has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' Growth Rank compare to GLSI and DTIL?
Protalix BioTherapeutics' Growth Rank of 1 can be compared against companies in the Biotechnology industry. Historically, Protalix BioTherapeutics' own Growth Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Protalix BioTherapeutics and its competitors. Protalix BioTherapeutics's current Growth Rank is 1, which is 80% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (FRA:PBDA) is currently considered Fairly Valued. The stock's GF Value™ is €1.89, compared to a current price of €2.00 — trading 5.8% above its estimated fair value. The current Growth Rank is 1, which is 80% below median its 10-year median of 5.00. Protalix BioTherapeutics' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Protalix BioTherapeutics (FRA:PBDA), the current Growth Rank is 1 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Protalix BioTherapeutics (FRA:PBDA) Overvalued in 2026?

Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued. The current stock price of €2.00 is trading 5.8% above its estimated GF Value™ of €1.89. GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.

Key valuation signals for FRA:PBDA:

  • Growth Rank: 1 (80% below median its 10-year median of 5.00)
  • GF Value™: €1.89 vs. price of €2.00 (5.8% above fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the FRA:PBDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protalix BioTherapeutics Business Description

Other Exchanges PLX:USA
Address 2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
56GF Score

Get the complete analysis for FRA:PBDA

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.00
Price
€1.89
GF Value